VRDN Oct 2024 5.000 put
| Previous close | 0.5500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 5.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.5500 - 0.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 03, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 538,000 shares of the company’s common stock to 10
Business WireViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
WALTHAM, Mass., June 11, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED.
Business WireViridian Therapeutics Announces Participation in Upcoming June Investor Conferences
WALTHAM, Mass., May 31, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in June:
